Optimi Health Corp. · CSE:OPTI
Optimi Health — Investor Presentation (August 2024)
22 slides from Optimi Health's investor presentation, August 2024
Slide 1: Optimi Health: Milestones, Opportunities, and Market Landscape
OPTIMI HEALTH Milestones, Opportunities, and Market Landscape INVESTOR PRESENTATION AUGUST 2024 - CONFIDENTIAL CSE: OPTI I OTC: OPTHF I FRA: 8BN
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements
Slide 3: Health Canada-approved, GMP-compliant drug manufacturer
Optimi is a Health Canada-approved, GMP- compliant pharmaceutical drug manufacturer specializing in the controlled substances MDMA and botanical psilocybin. The Company owns two 10,000-square-foot production facilities and operates under a Drug Establishment Licence awarded by Health Canada.
Slide 4: Slide 4
Slide 5: The Optimi Advantage
THE OPTIMI ADVANTAGE Two Drugs In-Market for Patient Use Optimi has MDMA and Psilocybin capsules available to treat PTSD and TRD in Australia. Compass, Atai, Lykos and others in the industry cannot make this claim. Years Ahead of the Competition The competition is still in the clinical development p
Slide 6: 2024: Key Milestones Completed
2024: Key Milestones Completed May 2024 June 2024 April 2024 May 2024 Secured Import Certificate Health Canada Issues Completed Validated Export Permit Issued Three Export Permits to GMP Production of by Health Canada for from Mind Med Australia for Optimi to Supply 5mg Natural Company's First 160 D
Slide 7: 2024: Key Milestones Upcoming
2024: Key Milestones Upcoming June 2024 June 2024 August 2024 Export Permit Issued Drug Master File First Patients Dosed in for Shipment of 160 Submission (DMF) to Australia's Authorised Doses of MDMA & Health Canada & US Prescribers Scheme in Psilocybin for FDA for MDMA & Australia with MDMA & Pati
Slide 8: MDMA 40mg & 60mg GMP Capsules
MDMA (methylenedioxy-methylamphetamine) 40mg & 60mg GMP Capsules >99% Application Validation Manufactured for use by patients in Australia's Qualified process validation which includes the PURITY Authorized Prescribers Scheme, as well as manufacturing process, and supporting licensed entities conduc
Slide 9: Psilocybin Extract (psilocybe cubensis)
PSILOCYBIN EXTRACT (psilocybe cubensis) 5mg GMP Capsules & 10mg R&D Capsules Application Validation Manufactured for use in qualified patients with Third-party COA confirms critical information treatment resistant depression (TRD) within the regarding potency, water content, microbial Australian Aut
Slide 10: Quote from JJ Wilson on Australian prescribing
“Australian psychiatrists can now prescribe Optimi’s MDMA and Psilocybin capsules for therapeutic use in patients. To have both of these GMP drugs in market is a very humbling achievement” - JJ WILSON CO-FOUNDER & CHAIRMAN, OPTIMI HEALTH ©2024 Proprietary and Confidential. All Rights Reserved. 10
Slide 11: Market Capitalization & Drug Pipeline Comparison
Market Capitalization & Drug Pipeline Comparison Comparison of psychedelic company market caps and current drugs in-market as of August 2024 (CAD) Optimi Lykos Atai Mind Med Compass Cybin Market Capitalization $30,000,000 $400m $300m $680m $650m $260m MDMA in Market Psilocybin in Market In-House GMP
Slide 12: Psilocybin NDA Pathway for Treatment Resistant Depression
Psilocybin NDA Pathway for Treatment Resistant Depression Comparison: Company XXX is hundreds of millions of dollars and years away from being in-market, Optimi is in-market now for TRD. Assumes Positive Outcomes, Efficacy, and Minimal Bias in Trial Design Company XXX Development of Psilocybin Drug
Slide 13: Optimi's NDA Pathway for Treatment of PTSD & TRD
Optimi's NDA Pathway for Treatment of PTSD & TRD With the drug establishment licence, Optimi is authorized by Health Canada to supply MDMA & Psilocybin capsules to Patients in regulated markets. Optimi will collect Real World Evidence (RWE) to support multiple NDA submissions by leveraging real Pati
Slide 14: How is Optimi Positioned to Win the Rollout of MDMA & Psilocybin?
How is Optimi Positioned to Win the Rollout of MDMA & Psilocybin? 5% of the world is depressed... Optimi is ready to deliver cost effective, GMP MDMA & Psilocybin Capsules under their Drug Establishment Licence to regulated markets around the world upon rescheduling. Cost-Effective Production GMP Co
Slide 15: Pathway to US Exchange Listing in 2026
Pathway to US Exchange Listing in 2026: As a Health Canada licensed GMP pharmaceutical drug manufacturer, Optimi's MDMA and Psilocybin capsules available by prescription in Australia. The Company is in discussions with US based institutions who have financed US exchange listed psychedelic companies.
Slide 16: Executive & Management Team
Executive & Management Team Bryan Jacob Dr. Preston Bill Ciprick Safarik Safarik Chase CEO COO CFO CSO Karina Leah Dane Lahnakoski Hodges Stevens Director of Corporate CMO Quality Secretary ©2024 Proprietary and Confidential. All Rights Reserved. 16
Slide 17: Board of Directors
Board of Directors JJ Wilson Bryan Safarik Jacob Safarik Chairman & Co-Founder COO & Co-Founder CFO & Co-Founder Independant Director Director Director Dane Stevens Jon Schintler CMO & Co-Founder Independant Director Director ©2024 Proprietary and Confidential. All Rights Reserved. 17
Slide 18: Advisory Board
Advisory Board Chip Wilson Edward Safarik Harley Pasternak Azim Jamal ©2024 Proprietary and Confidential. All Rights Reserved. 18
Slide 19: Recent Media & Press
RECENT MEDIA & PRESS ©2024 Proprietary and Confidential. All Rights Reserved. 19
Slide 20: Why Invest in Optimi Now?
Why Invest in Optimi Now? Access to Real World Data & Two Psychedelic Drugs Available Patient Outcomes Using Optimi's in a Prescription Market Products Licensed & Ready to Export Strong Financial Support and MDMA & Psilocybin Capsules Backing From Insiders & Founders Globally Cost-Effective On-Site
Slide 21: Key Milestones Explained
Key Milestones Explained: Optimi's MDMA & Psilocybin Now Prescribable Real World Evidence Collection & Patient Australia's Therapeutic Goods Administration has authorized the import of Outcomes Optimi's MDMA 40mg & 60mg Capsules, and 5mg Natural Psilocybin In partnership with Mind Medicine Australia
Slide 22: Thank you.
Thank you. INVESTOR PRESENTATION AUGUST 2024 - CONFIDENTIAL CSE: OPTI I OTC: OPTHF I FRA: 8BN